Melanotan 1 (MT-1)

What Is Melanotan 1?

Melanotan 1 is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), the natural hormone responsible for triggering the skin to produce more pigment, called melanin, in response to sun exposure. It was developed at the University of Arizona in the 1980s as researchers looked for a more stable, longer-lasting version of the natural hormone.

An important distinction sits at the center of understanding MT-1: its FDA-approved pharmaceutical form is called afamelanotide, sold under the brand name Scenesse, and delivered as a controlled-release implant for a specific rare skin condition. Separately, MT-1 is also sold unregulated as a research or self-tanning compound, which is a different product entirely in terms of oversight, purity, and safety data.

What Melanotan 1 Is Being Researched For

• Skin Pigmentation

  The foundational area of MT-1 research is its ability to trigger melanin production and skin darkening, first demonstrated in an early human trial that established its tanning activity.^[1]

• Light Sensitivity Disorders

  MT-1's most developed clinical research addresses erythropoietic protoporphyria, a rare genetic condition that causes severe pain on sun exposure. A pair of Phase 3 trials found the approved afamelanotide implant increased how long patients could tolerate sunlight without pain.^[2]

• Comparative Safety Research

  Because MT-1 is also sold outside regulated channels, researchers have separately reviewed the safety differences between the approved pharmaceutical form and unregulated versions sold for tanning purposes.^[3]

How Melanotan 1 Works

• Activating the Skin's Pigment Receptor

  Research points to MT-1 binding to the melanocortin 1 receptor (MC1R) on skin cells called melanocytes, the same receptor the body's natural alpha-MSH uses. This activation increases the activity of tyrosinase, an enzyme central to melanin production, leading to increased skin pigmentation.^[1]

• A More Selective, Longer-Lasting Signal

  Research points to MT-1 being engineered to resist the rapid breakdown that limits natural alpha-MSH, extending its activity, and to bind preferentially to MC1R over other melanocortin receptors. This selectivity is part of why its approved pharmaceutical form has a more limited side effect profile than other analogs in its class.

Reconstitution and Handling

Research-grade MT-1 is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken. This is separate from the FDA-approved afamelanotide implant, which is manufactured and administered as a controlled-release device rather than reconstituted.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

Melanotan 1 stands apart from most compounds on this site because its approved form, afamelanotide, carries real Phase 3 human trial data and FDA approval for a specific rare condition. Its research base spans the original pigmentation mechanism, developed clinical use in light sensitivity, and safety comparisons against unregulated versions sold outside pharmaceutical channels. That distinction between the approved and unregulated forms is central to understanding what the research actually supports.

Frequently Asked Questions

Sources and Research

1. Levine N, Sheftel SN, Eytan T, Dorr RT, Hadley ME, Weinrach JC, Ertl GA, Toth K, McGee DL, Hruby VJ. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991;266(19):2730-2736.
2. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015;373(1):48-59.
3. Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017;56(10):975-980.